A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.
Prevention of the progression of precancerous lesions by vaccines is virtually uncharted territory. Their potential, however, is being assessed in transgenic mice which develop autochthonous tumors with defined stages of progression. In this paper we show that the DNA micro-array technology significantly helps assessment of the preventive efficacy of a combined DNA and cell vaccine. All female rat Her-2/neu transgenic BALB/c (BALB-neuT) mice develop an invasive carcinoma in each of their mammary glands within 25 weeks of age. This is elicited by the activated transforming rat Her-2/neu oncogene embedded in their genome. We have previously shown that vaccination of mice bearing multiple in situ carcinomas with DNA plasmids which code for the extracellular and transmembrane domain of rat p185neu, the product of the rat Her-2/neu oncogene, followed by a boost with rat p185neu+ allogeneic cells engineered to secrete interferon-gamma, keeps 48% of mice tumor free until week 32. We have now extended our follow-up until mice reach one year of age and show that protection vanishes as time progresses. This observation suggests that the accuracy of the results studying immunotherapy against life-threatening tumors is a function of the length of the follow-up. The application of microarrays, and the concordance of morphologic and gene expression data led us to identify antibody as the main mechanism induced by vaccination. Protection is associated with a break of tolerance and a limited autoimmunity against the endogenous mouse p185neu.
Lo Iacono
M
M
Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.
Cavallo
F
F
Quaglino
E
E
Rolla
S
S
Iezzi
M
M
Pupa
S M
SM
De Giovanni
C
C
Lollini
P-L
PL
Musiani
P
P
Forni
G
G
Calogero
R A
RA
D000818:Animals; D015551:Autoimmunity / Q000187:drug effects*; D045744:Cell Line, Tumor; D003001:Cloning, Molecular; D005260:Female; D006023:Glycoproteins / Q000235:genetics*; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic; D011230:Precancerous Conditions / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D019076:Transgenes; D019444:Vaccines, DNA / Q000627:therapeutic use*
D006023:Glycoproteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D019444:Vaccines, DNA; C483804:Erbb2 protein, rat